A. Cataliotti

Publications244
h-index39
Citations5,487
Highly Influential Citations155
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Burnett
  • 934 Publications, 31,539 Citations
  • M. Redfield
  • 507 Publications, 43,997 Citations
  • H. Chen
  • 296 Publications, 7,579 Citations
  • J. Burnett
  • 249 Publications, 14,655 Citations
  • Publications
  • Influence
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.
Hypertension and heart failure (HF) are common diseases that, despite advances in medical therapy, continue to be associated with high morbidity and mortality. Therefore, innovative therapeutic… Expand
  • 188
  • 18
  • PDF
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure.
C-terminal brain (B-type) natriuretic peptide (BNP)-32 is a widely used clinical biomarker for the diagnosis, prognosis, and treatment of heart failure (HF). The 32-aa peptide is synthesized… Expand
  • 246
  • 11
Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis.
Left ventricular hypertrophy (LVH) is exceedingly frequent in patients undergoing dialysis. Cardiac mass is proportional to body size, but the influence of various indexing methods has not been… Expand
  • 277
  • 11
  • PDF
Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients.
This study was designed to investigate the relationship among brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) and left ventricular mass (LVM), ejection fraction, and LV geometry… Expand
  • 307
  • 9
Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression.
BACKGROUND Regression of left ventricular hypertrophy (LVH) in the setting of a well-planned intervention study has been associated with longer survival in hemodialysis patients. Whether changes in… Expand
  • 277
  • 9
  • PDF
Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases
Abstract— Cardiac fibroblasts (CFs) produce extracellular matrix proteins and participate in the remodeling of the heart. It is unknown if brain natriuretic peptide (BNP) is synthesized by CFs and if… Expand
  • 292
  • 8
Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients.
Patients with end-stage renal disease (ESRD) are at high risk for heart failure, but the prevalence and the prognostic value of asymptomatic systolic dysfunction in these patients are unknown. In… Expand
  • 177
  • 7
  • PDF
Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients.
BACKGROUND We prospectively tested the prediction power of homocysteinemia for all-cause and cardiovascular outcomes in a cohort of 175 hemodialysis patients followed for 29 +/- 12 months. METHODS… Expand
  • 286
  • 5
  • PDF
Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.
OBJECTIVES To determine levels of natriuretic peptides (NPs) in patients with end-stage renal disease (ESRD) and to examine the relationship of these cardiovascular peptides to left ventricular… Expand
  • 189
  • 5
Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction.
OBJECTIVES The purpose of this study was to investigate circulating pro-B-type natriuretic peptide (proBNP(1-108)) in the general community and evaluate its ability to detect left ventricular (LV)… Expand
  • 62
  • 5